<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846673</url>
  </required_header>
  <id_info>
    <org_study_id>YMC045</org_study_id>
    <nct_id>NCT04846673</nct_id>
  </id_info>
  <brief_title>Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy</brief_title>
  <acronym>OPTIMUM</acronym>
  <official_title>Efficacy and Safety of Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy: a Randomized, Parallel, Open-label, Multicenter, Phase IV Clinical Trial (OPTIMUM Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, parallel, open-label, multicenter, phase IV clinical trial to&#xD;
      assess the efficacy and safety of pregabalin and alpha-lipoic acid combination compared with&#xD;
      each monotherapy in patients with diabetic peripheral neuropathy for 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual analogue scale (VAS)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual analogue scale (VAS)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual analogue scale (VAS) reduction rate of more than 30%</measure>
    <time_frame>6 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual analogue scale (VAS) reduction rate of more than 50%</measure>
    <time_frame>6 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brief pain inventory Korean version, BPI-K</measure>
    <time_frame>6 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total symptom score, TSS</measure>
    <time_frame>6 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain detect questionnaire, PD-Q</measure>
    <time_frame>6 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 level version of Euro-Qol-5 dimensions, EQ-5D-3L</measure>
    <time_frame>6 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Diabetic Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Pregabalin and alpha-lipoic acid combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alpha-lipoic acid 480 mg/tablet once daily before breakfast and Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregabalin 150 mg/tablet once daily before bedtime will be administrated for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alpha-lipoic acid monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alpha-lipoic acid 480 mg/tablet once daily before breakfast will be administrated for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 150mg + Alpha-lipoic acid 480mg</intervention_name>
    <description>Pregabalin qd + alpha-lipoic acid qd</description>
    <arm_group_label>Pregabalin and alpha-lipoic acid combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 150mg</intervention_name>
    <description>pregabalin qd</description>
    <arm_group_label>Pregabalin monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha-Lipoic Acid 480mg</intervention_name>
    <description>alpha-lipoic acid qd</description>
    <arm_group_label>Alpha-lipoic acid monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged 19 to 75&#xD;
&#xD;
          -  type 2 diabetes mellitus with HbA1c (Hemoglobin A1c) ≤ 10 %&#xD;
&#xD;
          -  peripheral (eg. hands, feet) neuropathic pain (eg. abnormal sensations, numbness,&#xD;
             pain, etc.) within 3 months (12 weeks)&#xD;
&#xD;
          -  diagnosed with diabetic peripheral neuropathy (DPN)&#xD;
&#xD;
          -  VAS pain score ≥ 40 mm&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  brittle diabetes mellitus&#xD;
&#xD;
          -  ALT (Alanine Transaminase), AST (Aspartate Transaminase), CPK (Creatine Phosphokinase)&#xD;
             level ≥ 3 times the upper limit of normal (UNL) or active liver disease&#xD;
&#xD;
          -  severe renal impairment (eGFR (estimated glomerular filtration rate) &lt; 60 mL/min/&#xD;
             1.73m2)&#xD;
&#xD;
          -  treated with antiepileptic drugs within 1 week at randomization&#xD;
&#xD;
          -  other nervous system or neuropathic disorders that may affect pain evaluation&#xD;
&#xD;
          -  oral drug administration is not possible, or hypersensitive or allergic to pregabalin,&#xD;
             r-thioctic acid tromethamine, thioctic acid, and other excipients&#xD;
&#xD;
          -  pregnant, lactating, or childbearing potential&#xD;
&#xD;
          -  alcoholics, drug abusers, and patients who are difficult to participate in clinical&#xD;
             trials due to psychological and emotional problems&#xD;
&#xD;
          -  have participated in other clinical trials within 30 days at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JC Won</last_name>
    <phone>82-2-950-8860</phone>
    <email>drwonjc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inje University Sanggye Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JC Won</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

